Liminatus Pharma (LIMN) Non Operating Income (2024 - 2026)
Liminatus Pharma (LIMN) posted Non Operating Income of -$22816.0 for Q1 2026, up 99.69% sequentially from -$7.3 million in Q4 2025, and up 63.96% YoY from -$13915.7 in Q1 2025.
Liminatus Pharma (LIMN) Non Operating Income (2024 - 2026) Analysis & Trends
Liminatus Pharma has reported Non Operating Income for 3 years, with the latest figure at -$22816.0 in Q1 2026.
- Quarterly Non Operating Income rose 63.96% year-over-year to -$22816.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$7.2 million (down 2947.57% YoY) and the FY2025 annual result came in at -$7.2 million, down 3245.74% from the prior year.
- Non Operating Income improved to -$22816.0 in Q1 2026 per LIMN's latest filing, from -$7.3 million in the prior quarter.
- Over five years, Non Operating Income peaked at $1.2 million in Q2 2025 and troughed at -$7.3 million in Q4 2025.
- A 3-year average of -$929301.2 and a median of -$60450.0 in 2024 frame the typical range for Non Operating Income.
- The widest YoY moves for Non Operating Income: up 2468.77% in 2025, down 11523.0% in 2025.
- Over 3 years, Non Operating Income stood at -$62675.0 in 2024, then sank by 11523.0% to -$7.3 million in 2025, then surged by 99.69% to -$22816.0 in 2026.
- According to Business Quant data, Non Operating Income over the past three periods registered -$22816.0, -$7.3 million, and -$1.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Liminatus Pharma | 256.03 Mn | 256.03 Mn | - | -28,351.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22,816.00 |
| Dec 31, 2025 | -7.28 Mn |
| Sep 30, 2025 | -1.12 Mn |
| Jun 30, 2025 | 1.23 Mn |
| Mar 31, 2025 | -63,306.00 |
| Dec 31, 2024 | -62,675.00 |
| Sep 30, 2024 | -58,225.00 |
| Jun 30, 2024 | -51,989.00 |